ストックスクリーナーアプリを入手
136.36
5.21%
6.75
アフターアワーズ：
136.60
0.24
+0.18%
前日終値:
$129.61
開ける：
$132.62
24時間の取引高:
9.17M
Relative Volume:
1.31
時価総額：
$169.30B
収益：
$29.79B
当期純損益:
$9.22B
株価収益率:
18.55
EPS:
7.3494
ネットキャッシュフロー:
$10.23B
1週間 パフォーマンス:
+7.93%
1か月 パフォーマンス:
+5.57%
6か月 パフォーマンス:
+9.66%
1年 パフォーマンス:
+21.99%
1日の値動き範囲:
$132.00
$136.60
1週間の範囲:
$125.12
$136.60
52週間の値動き範囲:
$107.75
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
136.36 | 160.92B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,235.56 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
267.24 | 624.26B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
254.65 | 450.11B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
128.86 | 313.12B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
157.03 | 296.69B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-10 | 開始されました | Jefferies | Buy |
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-02-11 | 繰り返されました | Needham | Buy |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-08-19 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | アップグレード | Truist | Hold → Buy |
| 2025-07-25 | アップグレード | Needham | Hold → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2025-02-18 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-13 | アップグレード | DZ Bank | Hold → Buy |
| 2025-01-10 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 繰り返されました | Maxim Group | Buy |
| 2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-02-22 | ダウングレード | Truist | Buy → Hold |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Reduce |
| 2023-07-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 再開されました | Piper Sandler | Overweight |
| 2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 再開されました | BofA Securities | Neutral |
| 2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
| 2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2022-10-28 | 繰り返されました | Cowen | Outperform |
| 2022-10-28 | 繰り返されました | JP Morgan | Overweight |
| 2022-10-28 | 繰り返されました | Jefferies | Buy |
| 2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-10-28 | アップグレード | Truist | Hold → Buy |
| 2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-02 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-02-02 | 繰り返されました | Truist | Hold |
| 2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Argus | Hold → Buy |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 再開されました | Piper Sandler | Neutral |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | アップグレード | Redburn | Neutral → Buy |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-09-30 | 再開されました | Jefferies | Buy |
| 2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
| 2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
| 2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2020-07-31 | 繰り返されました | SunTrust | Hold |
| 2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
| 2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | アップグレード | SunTrust | Sell → Hold |
| 2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
| 2020-04-27 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
A Look at Gilead Sciences Inc (GILD) After 5.2% Gain -- GF Value $96.06 vs Price $136.36 - GuruFocus
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MSN
Gilead Sciences rises as analyst upgrade adds to HIV franchise momentum - Quiver Quantitative
Gilead Sciences keeps building its antiviral pipeline. The focus shifts to long-term growth and US m - AD HOC NEWS
Gilead Stock Rallies As Trodelvy Wins First-Line Cancer Nod - StocksToTrade
BBG Advanced Therapies Launches Mobile Leukapheresis Center, in Collaboration with Kite to Bring CAR T-cell Therapies Closer to Patients - GlobeNewswire Inc.
Truist Securities Adjusts Gilead Sciences Price Target to $156 From $157 - marketscreener.com
Gilead price tries to pierce ceiling of descending correctional price channelForecast today07-07-2026 - Economies.com
RBC Capital Adjusts Gilead Sciences Price Target to $120 From $122, Maintains Sector Perform Rating - marketscreener.com
Gilead Sciences Inc. stock outperforms competitors despite losses on the day - MarketWatch
GILDGilead Sciences Inc Options - Finviz
What's Going on With Gilead Sciences Stock Monday?Gilead Sciences (NASDAQ:GILD) - Benzinga
Gilead Sciences (GILD) Participates in Ebola Treatment Clinical Trial in Congo - GuruFocus
Here Are Monday’s Best Wall Street Analyst Research Calls: Agnico Eagle Mines, Datadog, Delta Air Lines, Gilead Sciences, Okta, Pfizer, Regions Financial, T-Mobile, and More - Yahoo Finance
This Gilead Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Benzinga
Earnings call transcript: Gilead Sciences beats Q1 2026 forecasts, stock dips - Investing.com
Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel - The National Law Review
Insider Sell: Daniel O'Day Sells 15,000 Shares of Gilead Sciences Inc (GILD) - GuruFocus
Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion -- Update - marketscreener.com
If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today - Sahm
Gilead Sciences Inc (GILD) Stock Up 4.2% but GF Value Says Overv - GuruFocus
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Calvert VP SRI Balanced Portfolio's Gilead Sciences Inc(GILD) Holding History - GuruFocus
Gilead Owed $68M In Counterfeit Case, Magistrate Judge Says - Law360
Gilead Sciences highlights its antiviral portfolio as a long-term growth driver - AD HOC NEWS
List of 21 Acquisitions by Gilead (Jul 2026) - Tracxn
Morgan Stanley Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $168 - Moomoo
Gilead Sciences consensus picture, shares steady on NASDAQ - AD HOC NEWS
Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products - WSJ
Gilead Sciences, Inc.(NasdaqGS: GILD) dropped from Russell 1000 Growth-Defensive Index - marketscreener.com
Gilead Sciences Inc. stock underperforms Monday when compared to competitors - MarketWatch
Gilead Sciences Inc (NASDAQ:GILD): A Sustainable Dividend Leader in the Biotechnology Sector - ChartMill
Gilead Sciences, Inc.(NasdaqGS: GILD) dropped from Russell Top 200 Growth Benchmark - marketscreener.com
Gilead Sciences wins Trodelvy approvals, shares supported by oncology focus - AD HOC NEWS
Gilead Sciences, Inc.(NasdaqGS: GILD) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Gilead Sciences, Inc.(NasdaqGS: GILD) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Gilead Sciences, Inc.(NasdaqGS: GILD) dropped from Russell 1000 Dynamic Index - marketscreener.com
Gilead Sciences launches Trodelvy in TNBC, shares hold near $128 - AD HOC NEWS
Gilead (GILD) Wins FDA Approval for Trodelvy in TNBC - Insider Monkey
Price to sales forward of Gilead Sciences, Inc. – NASDAQ:GILD - TradingView
Gilead Sciences Raises Guidance After Results Top Views - WSJ
Enterprise value to revenue forward of Gilead Sciences, Inc. – NASDAQ:GILD - TradingView
Gilead Sciences clears a fresh 12?month high, shares react to new FDA approval - AD HOC NEWS
Will Trodelvy’s First-Line TNBC Approval Redefine Gilead Sciences’ (GILD) Oncology-Led Investment Narrative? - Yahoo Finance
Gilead Sciences (GILD) Wins First Line Trodelvy Approval In The US And Europe - Yahoo Finance
GILD News | GILEAD SCIENCES INC (NASDAQ:GILD) - ChartMill
Price to book forward of Gilead Sciences, Inc. – NASDAQ:GILD - TradingView
Price to earnings forward of Gilead Sciences, Inc. – NASDAQ:GILD - TradingView
Gilead Sciences Inc (GILD) Shares Surge 3.3% -- What GF Score of 75 Tells Investors - GuruFocus
Gilead Sciences Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Gilead Sciences, Inc. Actuals & Estimates (VIE:GILD) - TradingView
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
0.45%
大文字化:
|
ボリューム (24 時間):